Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for lung cancer patients: lorlatinib shows promise in Real-World study

NCT ID NCT06282991

Completed Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how well the drug lorlatinib works for people with advanced non-small cell lung cancer that has a specific gene change (ALK). All 73 participants had already tried other treatments and took lorlatinib pills at home. The study tracked how long the drug kept the cancer from growing, how many people responded, and what side effects occurred. Results help doctors understand the real-world benefits and risks of lorlatinib for this type of lung cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON SMALL CELL LUNG CARCINOMA

Contacts and locations

Locations

  • CHANG GUNG MEMORIAL HOSPITAL Kaohsiung Branch

    Kaohsiung City, 83301, Taiwan

  • Chang Gung Memorial Hospital - Linkou Branch

    Taoyuan City, 333, Taiwan

  • Chung Shan Medical University Hospital

    Taichung, 402, Taiwan

  • National Taiwan University Hospital

    Taipei, 100, Taiwan

  • Taichung Veterans General Hospital

    Taichung, 407219, Taiwan

  • Taipei Veterans General Hospital

    Taipei, 11217, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.